Cargando…

Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets

Hematologic malignancies comprise a diverse range of blood, bone marrow, and organ-related disorders that present significant challenges due to drug resistance, relapse, and treatment failure. Cancer-associated fibroblasts (CAFs) represent a critical component of the tumor microenvironment (TME) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Ziyang, Shi, Run, Hu, Weikang, Tian, Lei, Sun, Rong, Wu, Yang, Zhang, Xiaoyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511871/ https://www.ncbi.nlm.nih.gov/pubmed/37746306 http://dx.doi.org/10.3389/fonc.2023.1193978

Ejemplares similares

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
por: Xu, Duo, et al.
Publicado: (2020)

The Role of Exosomes in the Progression and Therapeutic Resistance of Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2022)

Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies
por: Schütte, Judith, et al.
Publicado: (2019)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

WNT Signaling in Hematological Malignancies
por: Frenquelli, Michela, et al.
Publicado: (2020)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies
por: Xie, Yutong, et al.
Publicado: (2022)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Cap-Independent Translation in Hematological Malignancies
por: Horvilleur, Emilie, et al.
Publicado: (2015)

Multiple Roles of Glycans in Hematological Malignancies
por: Pang, Xingchen, et al.
Publicado: (2018)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Editorial: Epidemiological trends in hematological malignancies
por: de Lima, Marcos, et al.
Publicado: (2023)

Steering Mast Cells or Their Mediators as a Prospective Novel Therapeutic Approach for the Treatment of Hematological Malignancies
por: Mehtani, Deeksha, et al.
Publicado: (2021)

Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2021)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies
por: Zuo, Fengli, et al.
Publicado: (2022)

Arginase: Mechanisms and Clinical Application in Hematologic Malignancy
por: Du, Zefan, et al.
Publicado: (2022)

Advances in the Study of circRNAs in Hematological Malignancies
por: Du, Jingyi, et al.
Publicado: (2022)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Germline and somatic drivers in inherited hematologic malignancies
por: Zoller, Julian, et al.
Publicado: (2023)

Editorial: Case reports in hematological malignancies: 2022
por: Antar, Ahmad, et al.
Publicado: (2023)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy
por: Zhao, Huijuan, et al.
Publicado: (2022)

Advanced Targeted, Cell and Gene-Therapy Approaches for Pediatric Hematological Malignancies: Results and Future Perspectives
por: Magnani, Chiara F., et al.
Publicado: (2013)

Cancer associated fibroblasts in hematological malignancies
por: Raffaghello, Lizzia, et al.
Publicado: (2014)

Crosstalk Between MYC and lncRNAs in Hematological Malignancies
por: Arman, Kaifee, et al.
Publicado: (2020)

Screening Strategies for COVID-19 in Patients With Hematologic Malignancies
por: Assi, Tarek, et al.
Publicado: (2020)

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies
por: Zhao, Yan, et al.
Publicado: (2021)

Editorial: COVID-19 and hematological malignancies: Volume II
por: Wilde, Lindsay, et al.
Publicado: (2022)

Liquid biopsy in hematological malignancies: current and future applications
por: Talotta, Donatella, et al.
Publicado: (2023)

Editorial: The management of hematologic malignancies in lower-income countries
por: Ganesan, Prasanth, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f1v1loahs88g56lie0m22hbcmf